Eleven Biotherapeutics is focused on translating breakthrough discoveries from science and medicine to engineer and develop innovative protein-based therapeutics to improve human health and treat disease. Eleven Biotherapeutics' scientists are engineering protein-based drugs using newly available structural information and the company's unique molecular understanding of clinical effects to create the next generation of protein-based medicines to treat important diseases with unmet needs, such as inflammatory conditions and coagulation disorders.
| Web Site: | www.elevenbio.com |
|---|---|
| Headquarters: | 215 First Street Cambridge, MA 02421 United States |
| Employees: | 11-40 |
| Year Founded: | 2010 |
| Industry: | Biotechnology |
| Investors: | Flagship Ventures, Third Rock Ventures |
Eleven Biotherapeutics' approach to building its pipeline of novel protein therapeutics is aimed at minimizing overall risk through a combination of drug development strategies, including:
- Coagulation Disorders
- Inflammatory Conditions
- Muscle Wasting Conditions
Core pipeline products: using new biological discoveries and protein design techniques to build the next generation of therapies in areas with clinically validated targets and mechanisms
Applied research projects: applying new protein design capabilities to novel therapeutic pathways and targets
Acquisitions: selective acquisition of clinical stage compounds that complement the company's other areas of research.
Combining these strategies allows Eleven Biotherapeutics to engineer protein therapeutics to create a full pipeline of products that address unmet needs and outperform other therapies for a variety of diseases, such as inflammatory conditions and coagulation disorders.
Link up your social media account to automatically promote the positions at Eleven Biotherapeutics.
Get a job alert every time Eleven Biotherapeutics posts a job.
Eleven Biotherapeutics does not have any jobs posted at this time.
